Stock 688177 BIO-THERA SOLUTIONS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
21.12 CNY -1.08% Intraday chart for Bio-Thera Solutions, Ltd. -6.26% -48.79%
06-03 Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin CI
06-02 Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-Alpha-ADC) At the 2024 American Society of Clinical Oncology Annual Meeting CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin
CI
Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-Alpha-ADC) At the 2024 American Society of Clinical Oncology Annual Meeting
CI
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
AQ
Bio-Thera Solutions Grants STADA European Commercialization Rights for BAT2506 Injection
MT
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK
MT
Bio-Thera Solutions and STADA Arzneimittel AG Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
CI
China Gives Nod to Bio-Thera Solutions' Clinical Trials for Anti-Tumor Drug Combo
MT
Bio-Thera Solutions Gets Nod to Trial Tumor Drug Combination
MT
China Grants Clinical Trial Approval to Bio-Thera's Anti-Tumor Combination Therapy
MT
Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor
AQ
Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006
CI
Bio-Thera Solutions Grants Marketing Rights of Two Drugs to Latin American Company
MT
Bio-Thera Solutions, Ltd. Partners with SteinCares to Market Two Biosimilars in LATAM
CI
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026
CI
Bio-Thera Solutions Gets Regulatory Nod for Trial of Tumor Drug Combination Treatment
MT
Recent Biosimilar Approvals
AQ
Bio-Thera Solutions Wins US FDA Nod to Market Cancer Drug
MT
FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688177 Stock
  4. News Bio-Thera Solutions, Ltd.